MedPlus Health Services has announced that its subsidiary, Optival Health Solutions Private Limited, has received multiple drug license suspensions from state authorities. The regulatory actions affect stores in Maharashtra and Odisha, representing compliance issues under the Drugs and Cosmetics Act.

Latest Regulatory Action in Odisha

The company received a new suspension order on March 09, 2026, from the Deputy Drugs Controller, Western Zone, Sambalpur, Odisha. This latest action affects a store located opposite the Private Bus Stand in Baragarh, Odisha, with a three-day suspension period.

Previous Maharashtra Suspension

Earlier, the subsidiary had received a seven-day drug license suspension from Maharashtra authorities for a store in Sangvi, Pune. This suspension order was received on March 03, 2026, from the Assistant Commissioner & Licensing Authority, Food & Drug Administration, Maharashtra.

Financial Impact Assessment

The company has quantified the potential revenue losses from both suspensions. The combined financial impact represents the expected business disruption during the suspension periods across both affected locations.

Regulatory Compliance Framework

Both suspensions fall under Rule 65 of the Drugs and Cosmetics Act, 1940, and Drugs and Cosmetics Rules, 1945, which govern pharmaceutical retail operations across India. Such actions by state drug control authorities typically occur when retail pharmacy operations fail to meet specific regulatory requirements or standards.

The company has disclosed this information under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, ensuring transparency with stakeholders regarding regulatory matters affecting its subsidiary operations. The disclosures follow SEBI circulars dated July 13, 2023, and December 31, 2024, regarding regulatory action reporting requirements.

MedPlus Health Services Limited has informed stock exchanges about a regulatory action affecting its subsidiary operations. The company disclosed that Optival Health Solutions Private Limited, a subsidiary, received a drug license suspension order from the Assistant Director, Drugs Control Administration, Rangareddy, Telangana.

Regulatory Action Details

The suspension order targets a specific store operated by the subsidiary in Kuntloor, Telangana. The regulatory action was initiated under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.

Financial Impact

The company has quantified the potential financial impact of this regulatory action. MedPlus estimates a potential revenue loss of Rs 0.42 lacs due to the one-day suspension of the drug license for the affected store.

Compliance Disclosure

This disclosure was made under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also referenced SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, in its regulatory filing.

The information has been made available on the company's website at www.medplusindia.com and will also be accessible on the BSE and NSE websites. Company Secretary & Compliance Officer Manoj Kumar Srivastava signed the disclosure on February 28, 2026.